Researchers developed the seats to measure biometrics during ‘natural’ processes
With 1 million new cases of congestive heart failure diagnosed each year, a revolutionary product is making it easier for hospitals to monitor patients with the condition in the comfort of their own homes.
A toilet-seat based cardiovascular monitoring system created by a team of Rochester Institute of Technology researchers, aims to lower the hospital readmission rates of patients with congestive heart failure. The toilet seats, which will be brought through the FDA clearance process by the researchers’ company Heart Health Intelligence, would be purchased by hospitals and issued to heart failure patients after discharge. The toilet seats are equipped to measure the electrical and mechanical activity of the heart, and can monitor heart rate, blood pressure, blood oxygenation levels, and the patient’s weight and stroke volume, which is the amount of blood pumped out of the heart at every beat. Algorithms analyze the data, and with further development, will alert advanced practice providers of a deteriorating condition. A report will be passed along to cardiologists who will then determine if intervention is necessary.
Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that developed the toilet seats.
“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted,” said Conn. “After 90 days of hospital discharge, 45 percent of patients are readmitted. And the Centers for Medicare and Medicaid Services is penalizing hospitals for readmitting patients for heart failure.”
Conn, the company’s chief executive officer, further explains that using the national average for readmission rates, the penalty alone for readmitting 150 patients is approximately $500,000 annually. The total cost of providing 150 patients with their own monitored toilet seats from HHI is $200,000. With that investment, he says, hospital systems will save more than double their initial investment within one year.
According to Conn, who earned three degrees from RIT—a bachelor’s degree and a master’s degree in electrical engineering in 2011 and 2013, respectively, and a doctoral degree in microsystems engineering in 2016—the system will pick up deteriorating conditions before the patients even realize they are symptomatic. And with the rapid data analysis, interventions can be as simple as a drug change or short office visit, instead of an admission to the hospital.
HHI, which joined RIT’s Venture Creations business incubator earlier this year, is now focused on moving the product forward. The team is heavily involved in writing grants for additional funding and networking, and human-subject testing and pre-clinical studies are well underway. Conn and his team are working on approving the product with the FDA and rolling it out across the country.
The Latest on: Congestive heart failure
via Google News
The Latest on: Congestive heart failure
- My father's tale of woe with adult onset epilepsy and heart disease. Anybody have any advice?on May 23, 2022 at 8:13 pm
I've joined and am posting this because my father has been fighting a bout with extremely virulent and quickly onsetting epilepsy over the last 8 months. He is 66. No prior history of epilepsy or ...
- Novocardia™ Launches Groundbreaking, Value-Based Heart Failure Management Program to Improve Patient Outcomes and Reduce Hospitalizationson May 17, 2022 at 10:40 am
The heart failure program is a new model for cardiology practices in managing heart failure, starting with patients in Northeast Florida NEW YORK, May 17, 2022 /PRNewswire/ -- Novocardia, a ...
- HFSA Releases Position Paper on The Impact of Healthcare Disparities on Patients with Heart Failureon May 17, 2022 at 10:26 am
A new position paper published today by the Heart Failure Society of America (HFSA) outlines disparities in healthcare that affect patients with ...
- Twin Cities woman, 48, had congestive heart failure and doctors kept saying it was pneumoniaon May 17, 2022 at 7:27 am
The Stacy, Minn., woman is a volunteer with the American Heart Association who shared her harrowing story of finding out she had congestive heart failure.
- COQ 10: Treats Heart Failure?on May 12, 2022 at 5:08 am
Heart failure HF is a public health issue of global importance. In Ghana, a study by Amoah and Kallen 2000 revealed that the main causes of heart failure were hypertension 21.
- Global Congestive Heart Failure (CHF) Market Evolution Segmentation and Insight of Trends 2022 to 2028on May 10, 2022 at 9:40 am
May 09, 2022 (CDN Newswire via Comtex) -- MarketsandResearch.biz has publicized the addition of a new report entitled Global Congestive Heart Failure (CHF) Market 2022 by Company, Regions, Type and ...
- Doxazosin and Congestive Heart Failureon May 9, 2022 at 5:00 pm
This finding was largely driven by congestive heart failure. The practicing clinician should not abandon doxazosin completely because of the ALLHAT findings, although these findings are ...
- Heart Failureon May 5, 2022 at 5:00 pm
Chronic heart failure may commonly be referred to as congestive heart failure. While our goal is to help people manage their symptoms at home with a healthy diet and the right combination of ...
- Congestive Heart Failure in the Elderly: The Cardiovascular Health Studyon May 5, 2022 at 5:00 pm
Congestive heart failure in the elderly is recognized as a national public health priority; however, clinical diagnosis can be problematic in elderly persons, many of whom have a history of heart ...
- Congestive Heart Failure Market 2022-Global Analysis By Sales Market Size, Segment And Evolution Rate By Type And Application Forecast To 2029on April 26, 2022 at 12:02 pm
New industry research report namely Global Congestive Heart Failure Market Size, Share, Growth, Industry Trends and Forecast to Congestive Heart Failure has the simplest recommendation on the ...
via Bing News